Page 2 - நோய் வாரம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நோய் வாரம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நோய் வாரம் Today - Breaking & Trending Today

Bristol Myers Squibb Presents New Data at Digestive Disease Week® on Zeposia (ozanimod) Highlighting Clinical Benefits and Safety Profile in Patients with Ulcerative Colitis


Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating
Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week ® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of
Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding and addressing unmet needs in gastroenterology.
Research being shared includes:
Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis Over Time: Pooled Analysis from Phase 2, Phase 3, and Open-Label Extension Trials
Pooled analysis including data from the Phase 2 TOUCHSTONE study, Phase 3 True North study and open-label extension trial. Long-term treatment with ....

United States , Mary Beth Harler , Bristol Myers Squibb , American Society For Gastrointestinal Endoscopy , Bristol Myers Squibb Company , Health Economics , American Gastroenterological Association , Fibrosis Development , Society For Surgery Of The Alimentary Tract , Drug Administration , European Commission , Outcomes Research , Exchange Commission , European Medicines Agency , Myers Squibb , Digestive Disease Week , Severely Active Ulcerative Colitis Over Time , Pooled Analysis , Open Label Extension , Induction Effects , Clinical Symptoms , Inflammatory Biomarkers , Severely Active Ulcerative Colitis , Induction Phase , Free Remission , Severely Active Ulcerative Colitis Treated ,

Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio in Gastrointestinal Diseases at Digestive Disease Week (DDW) 2021 Virtual


Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio in Gastrointestinal Diseases at Digestive Disease Week (DDW) 2021 Virtual
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the presentation of 7 abstracts supporting Cellvizio at Digestive Disease Week (DDW) 2021 Virtual, being held May 21-23. These abstracts focus on Barrett s esophagus (BE), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and associated food allergies, pancreatic cysts and other gastrointestinal diseases. Studies are focused on how the use of Cellvizio potentially impacts patient management and improves outcomes. ....

United States , United Kingdom , Eau Claire , Red Hill , North Somerset , Ralf Kiesslich , Robertl Gershon , Marietta Iacucci , Miguel Puga Tejada , Nastazja Dagny Pilonis , Thomas Grojean , Enfermedades Digestiva , Mike Piccinino , Horst Schmidt Kliniken Wiesbaden , Jorge Machicado , Gastroenterol Hepatol , Mathew Vithayathil , Karen Chang , University Hospitals , American Society For Gastrointestinal Endoscopy , French Financial Markets Authority Autorit , Institute Of Oncology , University Of Birmingham , Institute Of Immunology , University Of California System , University Of Cambridge ,